July 8 (Reuters) - Merck & Co Inc:
* FOGHORN THERAPEUTICS ANNOUNCES COLLABORATION WITH MERCK TO DISCOVER AND DEVELOP NOVEL ONCOLOGY THERAPEUTICS AGAINST TRANSCRIPTION FACTOR TARGET
* FOGHORN THERAPEUTICS - WILL GRANT MERCK EXCLUSIVE RIGHTS TO DEVELOP & COMMERCIALIZE DRUGS THAT TARGET DYSREGULATION OF A SINGLE TRANSCRIPTION FACTOR
* FOGHORN THERAPEUTICS - TO RECEIVE UPFRONT PAYMENT & RESEARCH MILESTONES, WILL BE ELIGIBLE TO GET CERTAIN MILESTONES POTENTIALLY TOTALING UPTO $425 MILLION Source text for Eikon: Further company coverage:
Our Standards: The Thomson Reuters Trust Principles.